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Abstract
The virus-host relationship in simian immunodeficiency virus (SIV) infected chimpanzees is
thought to be different from that found in other SIV infected African primates. However, stud-
ies of captive SIVcpz infected chimpanzees are limited. Previously, the natural SIVcpz infec-
tion of one chimpanzee, and the experimental infection of six chimpanzees was reported,
with limited follow-up. Here, we present a long-term study of these seven animals, with a ret-
rospective re-examination of the early stages of infection. The only clinical signs consistent
with AIDS or AIDS associated disease was thrombocytopenia in two cases, associated with
the development of anti-platelet antibodies. However, compared to uninfected and HIV-1
infected animals, SIVcpz infected animals had significantly lower levels of peripheral blood
CD4+ T-cells. Despite this, levels of T-cell activation in chronic infection were not significantly
elevated. In addition, while plasma levels of β2 microglobulin, neopterin and soluble TNF-
related apoptosis inducing ligand (sTRAIL) were elevated in acute infection, these markers
returned to near-normal levels in chronic infection, reminiscent of immune activation patterns
in ‘natural host’ species. Furthermore, plasma soluble CD14 was not elevated in chronic
infection. However, examination of the secondary lymphoid environment revealed persistent
changes to the lymphoid structure, including follicular hyperplasia in SIVcpz infected
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animals. In addition, both SIV and HIV-1 infected chimpanzees showed increased levels of
deposition of collagen and increased levels of Mx1 expression in the T-cell zones of the
lymph node. The outcome of SIVcpz infection of captive chimpanzees therefore shares fea-
tures of both non-pathogenic and pathogenic lentivirus infections.
Author Summary
The HIV-1/AIDS pandemic is the result of cross-species transmission of simian immuno-
deficiency virus (SIVcpz) from chimpanzees to humans. Many African primates are
infected with SIV, but those studied in captivity generally do not develop disease. How-
ever, wild chimpanzees infected with SIVcpz are at increased risk of death and may
develop an AIDS-like disease. It has therefore been suggested that the viral features which
SIVcpz and HIV-1 share, that differentiate them from other species’ SIV, may be critical in
the development of disease in both humans and chimpanzees. Here, we present a long-
term follow-up of 7 SIVcpz infected chimpanzees, housed in primate centres in the US
and Europe, under similar conditions to other studied models. These animals did not
develop an AIDS-like disease, after up to 25 years of infection, and showed features similar
to other species where disease rarely develops, such as limited immune activation in the
blood. However, they also had significantly reduced CD4+ T-cells and disruption to the
secondary lymphoid tissues, normally associated with pathogenic primate lentiviral infec-
tions. Thus, while SIVcpz infection of chimpanzees shares features of both pathogenic and
non-pathogenic infections, disease has not developed in captivity.
Introduction
Over 40 different African primate species are naturally infected with a species-specific simian
immunodeficiency virus (SIV) [1]. To date, studies into the outcome of SIV infection have
been limited to only a few species, in particular African green monkeys (Chlorocebus genus)
and sooty mangabeys (Cercocebus atys) studied primarily in U.S and European primate centres.
Such studies have demonstrated the apparent convergent evolution of multiple mechanisms to
prevent the development of SIV induced disease in these ‘natural hosts’ of SIV (reviewed [2,3]),
and cases of AIDS are extremely rare [4]. A key feature of non-pathogenic SIV infection of
African primates is the lack of chronic immune activation, and subsequent destruction of the
secondary lymphoid environment that occur in HIV-1 infection of humans.
The outcome of SIV infection of chimpanzees is less well understood than in other African
primates. Improving this knowledge is of particular relevance to our understanding of HIV-1
infection, as HIV-1 is the result of a cross-species transmission event of SIV from chimpanzees
(of the Central subspecies, Pan troglodytes troglodytes) [5]. Also, SIVcpz shares specific viral
features with HIV-1 that are not found in the other SIV infections studied [6]. In a study of
wild, Eastern chimpanzees (Pan troglodytes schweinfurthii), in the Gombe National Park, Tan-
zania, SIVcpz infected animals had a greater risk of mortality, with evidence of CD4+ T cell
depletion, indirect evidence of immune activation, and the development of an AIDS like dis-
ease in one animal [7]. These findings are radically different from the outcome of SIV infection
in African green monkeys [8,9] and sooty mangabeys [10], studied in primate research centres,
and thus it has been suggested that the virus-host relationship between SIVcpz and the chim-
panzee differs from that found in other species. It has been proposed that this is either due to a
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more recent acquisition of SIV in chimpanzees, or due to the presence of viral features of
SIVcpz, not found in other SIVs (including the presence of the vpu gene and the failure of the
SIVcpz nef gene to down-regulate the T-cell receptor [11]).
However, it cannot be excluded that the different study environments (wild chimpanzees
compared with captive sooty mangabeys) may bias the outcomes of SIV infection of these spe-
cies. Parasite infections were found to be a major cause of morbidity and mortality in the Gombe
chimpanzee cohort [7,12], and the apparent cause of death in one animal thought to be suffering
from an AIDS like condition [7]. The other known causes of mortality in the SIV infected chim-
panzees were intra-group aggression and other trauma. All these causes of death are less likely in
captive primate populations, due to standard veterinary care and behaviour management.
Prior to this landmark study of wild chimpanzees, limited studies of two SIVcpz infected
animals facilitated the assumption that chimpanzees were resistant to AIDS following SIVcpz
infection. These animals were ‘Marilyn’ and ‘Ch-No’, housed in the USA and The Netherlands
respectively. SIVcpz infection of Marilyn (subspecies troglodytes) was detected retrospectively,
after the death of the animal [13,14]. Marilyn was wild caught, and given the lack of other
SIVcpz infected animals in the centre, is presumed to have been infected prior to capture in
1963 at age of approximately 4 years. This animal died in 1985, and was therefore infected for
22 to 26 years without the development of AIDS. The cause of death was apparently due to
complications relating to the birth of stillborn twins. Examination of tissues post-mortem
revealed only minor disruptions to the secondary lymphoid tissues (plasmacystosis and some
degeneration of germinal centres), not consistent with the extensive changes seen in HIV-1
infected humans [13].
Ch-No (‘Noah’, subspecies schweinfurthii) is also a wild-born animal infected prior to age
2.5 years [15]. Limited data on this animal, in addition to the description of six chimpanzees
(three schweinfurthii and three verus subspecies) has previously been reported [16]. In that
study, blood from Ch-No was used to infect a second animal (Ch-Ni), and blood cells and/or
plasma from this animal, obtained two weeks post infection, were used to infect the subsequent
5 chimpanzees. Here we present a long term follow up study of Ch-No, and the 6 experimen-
tally infected animals, for 12 to 25 years post infection, in addition to retrospective analysis of
samples obtained throughout infection to characterise the outcome of SIVcpz infection in
these captive chimpanzees.
Results
Status of the SIVcpz infected cohort
As summarised in Table 1, of seven animals available to study four remained alive and in gen-
eral good health, as of January 2013, with the time from infection to this date ranging from
15.7 years to 26 years. Three of the animals have died since infection—both of the experimen-
tally infected schweinfurthii animals, Ch-Ni and X062, and one of the verus animals, X310. In
all cases, the resident pathologist determined that the cause of death was cardiac disease, and in
no case could the deaths be associated with the development of infectious or neoplastic disease
that might be expected as a result of a pathogenic lentivirus infection. Most recent peripheral
blood absolute CD4+ T-cell count, viral load and platelet count are also presented in Table 1.
Longitudinal data for viral load and absolute CD4+ T-cell count kinetics are shown in S1–S3
Figs. Notably, at the last available time for which CD4+ count data was available, three animals
had counts between 200 and 500 cells/μl, which defines stage 2 of CD4+ T-cell loss in HIV-1
infected humans in the Centre for Disease Control (CDC) classification, while one animal had
a count below 200 cells/μl, placing it in stage 3. Thrombocytopenia (defined by a platelet count
of<50 x109/l) was observed in two animals, categorizing them as CDC clinical stage B.
Investigation of SIVcpz Infected Chimpanzees
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To put these results into context, data from uninfected chimpanzees and HIV-infected
chimpanzees that have not progressed to disease (the most common phenotype in HIV-1
infected chimpanzees, termed here as HIV non-progressors, HIV-NP), from the centres at
which these animals were housed were collated. Details of the animals in each analysis are sup-
plied in the supplementary tables, as this varies between analysis, depending on the availability
of samples or data.
The absolute CD4+ T-cell count, the percentage that CD3+CD4+ cells make of the total
lymphocyte population, and the CD4:CD8 ratio of these animals were compared with unin-
fected and HIV infected controls. SIV infection was found to have a significant negative impact
on all three of these parameters (Fig 1) in a general linear model, with age, gender and HIV-1
infection status as additional covariates (detailed in S2 Table).
Peripheral blood T-cell activation in SIVcpz infected chimpanzees
Markers of T-cell activation were measured during the acute and chronic phase of infection for
one of the experimentally infected animals (Ch-Ni), shown in Fig 2A. As Ki-67 was not mea-
sured contemporaneously, cryopreserved samples were used to measure this marker, with sam-
ples from pre-infection, and at week 2, 55 and 300 post infection (p.i.). In addition as marker
expression was not measured contemporaneously on CD4+ T-cells at some time points, longi-
tudinal data for Ch-Ni is displayed for T-cells that are CD8 positive or CD8 negative. Both
Fig 1. Comparison of CD4+ T-cell levels in uninfected, HIV-1 infected and SIVcpz infected animals. Levels of peripheral blood CD4+ T-cells were
quantified by flow cytometry in chimpanzees that were uninfected (Neg., n = 32), HIV-1 non-progressors (HIV-NP, n = 29), or SIVcpz infected (SIVcpz, n = 7).
Levels were quantified as (A) Absolute CD4+ T-cell counts, (B) percentage CD4+ T-cells of the lymphocyte population, and (C) the CD4:CD8 T-cell ratios.
Shading corresponds to CDC categorisation for CD4+ T-cell levels (absolute count and percentage of lymphocytes) in HIV-1 infected humans, where yellow
indicates stage two and red indicates stage one. P value shown indicates that SIVcpz infection was a significant predictor of reduced CD4+ T-cell levels, in a
general linear model including age, gender, and HIV-1 and SIVcpz status. Full details of analysis are available in S1–S3 Tables. Each SIVcpz infected animal
is represented by a unique symbol, as indicated in the legend. Horizontal black bars indicate the mean value in each group. Data shown for the SIVcpz
infected animals are the most recent available, detailed in Table 1 as the time post infection for absolute T-cell count.
doi:10.1371/journal.ppat.1005146.g001
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Fig 2. Peripheral blood T-cell activation in SIVcpz infected animals. (A) Longitudinal measurements of T-cell activation in the CD8+ and CD8- T-cell
populations of the animal Ch-Ni. Each marker was normalised to pre-infection values: data is expressed as fold change compared to this. Viral load is shown
Investigation of SIVcpz Infected Chimpanzees
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Patr-DR (MHC class II), and Ki-67 were upregulated in the CD8+ T-cell population at week
two p.i., with reduced expression of these markers by one year p.i., albeit at levels that remain
higher than pre-infection values. Only CD69 was up-regulated on the CD8- population, with
fluctuating values throughout chronic infection.
Data from the chronic phase of infection was examined for all five SIV infected animals for
which flow cytometric analysis was carried out. When it was compared to uninfected and HIV-
1 infected animals, the effect of SIVcpz infection on these markers appeared to be small or not
apparent (Fig 2B, details of groups and statistical analysis S3 & S4 Tables). Non-progressive
HIV-1 infection was associated with small but significant increases in Ki-67 expression in both
the CD4+ and CD8+ T-cell populations, while SIVcpz appeared to induce a similar or smaller
(and not significant) effect. Curiously, HIV-1 infection was associated with a small but signifi-
cant suppression of Patr-DR (MHC-II) expression on CD8+ T-cells. Transcriptomic analysis
of cryopreserved peripheral blood mononuclear cells (PBMCs) was also carried out on a subset
of samples, (samples used are detailed in S5 Table). Fig 2C shows the transcriptomics data for
the T-cell markers studied by flow cytometry, along with some other well studied T-cell activa-
tion markers that have been shown to be elevated in HIV-1 infected individuals: CD38, IL2RA
(CD25) and FAS (CD95)[17–21]. Transcriptional level data revealed similar patterns as the
flow cytometry. Compared with three uninfected animals, the one available sample from week
two p.i. showed more than 2-fold increased levels of transcripts for CD69, Ki-67 (MKI67),
CD38, and FAS. Of these, none were more than 2 times elevated in both the week 4 post-infec-
tion samples (n = 4), though Ki-67 and CD38 were also more than two-fold upregulated com-
pared to control samples in the chronic phase (n = 7) of SIVcpz infection. A more complete
analysis of the effect of SIV/HIV-1 infection on genes shown to be upregulated during T-cell
activation in vitro is shown in S4 Fig. While a number of genes are upregulated or downregu-
lated in all groups compared to uninfected controls, there are a number of T-cell activation
associated genes that are only more than two-fold upregulated in the week two sample, such as
IFNG, GZMB,PRF1.
Soluble markers of immune activation
The soluble markers of immune activation β2 microglobulin (β2M), neopterin, and soluble
tumour necrosis factor-alpha-related apoptosis-inducing ligand (sTRAIL) were measured in
the plasma of SIVcpz infected animals during acute and chronic infection by ELISA (Fig 3,
details of groups in S6 Table). β2M levels were upregulated in all experimentally infected ani-
mals at week two p.i., returning to pre-infection levels at week 4 p.i.. When chronic phase β2M
levels of all SIVcpz infected animals (including Ch-No) were compared to uninfected or HIV-1
infected animals, there was no evidence for increased expression of this marker in SIVcpz
infected animals.
A similar pattern was found for neopterin levels, with the exception that this marker was
not elevated at week two in one animal (x284). Comparing samples taken in the chronic phase
of infection, there is a slight but not significant trend for SIVcpz infected animals to have
for reference. Ki-67 measurements were carried out on cryopreserved cells. (B) T-cell activation markers measured in uninfected, HIV-1 and SIVcpz infected
chimpanzees in the CD4+ compartment and CD8+ compartment. Ki-67 measurements established from cryopreserved cells are coloured blue. Horizontal
black bars indicate the mean value in each group. Data was unavailable for X310 and X062. P-value shown indicates that HIV-1 status was a significant
predictor of the plotted variable in a general linear model including age, gender, and HIV-1 and SIVcpz status. Data shown for the SIVcpz infected animals is
the most recent available, detailed in Table 1 as the time post infection for last absolute T-cell count, with the exception of measurements of Ki-67 in
cryopreserved samples from Ch-Ni, which were week 300 p.i. (C) Heatmap showing expression levels of the indicated genes in RNA-seq transcriptomics
analysis of peripheral blood mononuclear cells (PBMCs). Data is shown as fold upregulation compared to a group of uninfected animals n = 3. Full
information for the samples used is provided in S7 Table.
doi:10.1371/journal.ppat.1005146.g002
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Fig 3. Soluble markers of immune activation in the plasma of SIVcpz infected chimpanzees. (A, C, E) Plasma levels of β2-microglublin, neopterin, and
sTRAIL determined by ELISA, during the acute and chronic phase of infection in the experimentally infected animals. Levels of each marker were normalised
to the pre-infection level for each animal. Horizontal black bars indicate the mean value in each group. As sampling times and/or sample availability was not
identical for each animal, comparable time points are grouped (e.g. week 4 and week 6 are displayed as a single time point). (B, D, F) Levels of each marker
in the chronic phase (including Ch-No) of SIVcpz infection compared with values for uninfected and HIV-1 infected chimpanzees, and displayed as absolute
values. (G) Heatmap showing expression levels of the indicated genes in RNA-seq transcriptomics analysis of PBMCs.
doi:10.1371/journal.ppat.1005146.g003
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increased levels of plasma neopterin. Analysis of sTRAIL produced similar findings, with three
animals showing elevated levels of this marker at week two p.i., and with a slight, but not signif-
icant, trend for HIV-1 and SIVcpz infected animals to have higher levels in the chronic stage of
infection. The transcriptional analysis of genes related to these markers was also investigated
(Fig 3G). Similar to the findings by ELISA, transcripts for B2M and MHC-class I molecule
genes were only elevated in the week two p.i. sample, as were transcripts for interferon-γ,
which drives neopterin production. At the transcriptional level, TNFSF10 (TRAIL) was down-
regulated in all groups except the week two p.i. sample. However, it must be noted that the
transcriptional level data is derived from samples that do not exactly match those for which
plasma samples were available, and only represent expression in peripheral blood mononuclear
cells (PBMCs) which are not likely to be the sole source of plasma soluble proteins.
Analysis of structural changes in the secondary lymphoid environment
Limited lymphoid material was available from animals in the SIVcpz infected cohort: necropsy
materials from Ch-Ni and X062, and a biopsy from Ch-No, taken at the age of 8 years old,
allowing the determination of the effect of chronic SIVcpz infection in a total of three animals.
Biopsies were also available from three experimentally infected animals (X176, X115 and Ch-
Ni) representing acute (week two) and early (week 12/16) time points of infection. These sam-
ples were compared with necropsy materials from uninfected and HIV-1 infected control
animals.
Pathologist examination of lymph nodes from the three animals in the chronic phase of
infection revealed a number of phenomena found in HIV-1 infected patients, including varying
degrees of lymphoid hyperplasia in these animals; Ch-Ni (mild to moderate), X062 (marked)
and Ch-No (marked). Vascular proliferation was noted in both Ch-No and Ch-Ni (Table 2).
Representative images demonstrating the follicular hyperplasia in chronic infected animals are
shown in Fig 4. Follicular hyperplasia was not evident in any of the three animals at week two
p.i., while in week 12/16 samples, follicular hyperplasia was present in two of the three animals.
Follicular hyperplasia was also absent in all 7 uninfected control animals, but present in 2 of 5
lymph node biopsies from HIV-1 infected chimpanzees.
Available tissues were analysed by immunohistochemistry using an anti-collagen 1 antibody
and the percentage of T-cell zones staining for collagen-1 was quantified (Fig 5, details of
groups in S7 Table). In both chronic HIV-1 and SIVcpz infected animals there was significantly
increased levels of collagen deposition in the T-cell zone compared to uninfected animals, with
particularly high levels of deposition in the SIVcpz infected animal Ch-Ni. Interestingly, the
Table 2. Pathologist observations of tissues from chronic SIVcpz infected chimpanzees.
ID Type of
material
Time post infection
(years)
Histopathology
Ch-
No
Biopsy 7.9 • Moderate follicular hyperplasia
• Mild to moderate ﬁbrosis and altered vascular network (in
the corona and paracortex)
Ch-Ni Necropsy 9.8 • Mild to moderate follicular hyperplasia
• Moderate follicular and paracortical ﬁbrosis and mildly
increased vascularization
X062 Necropsy 3.4 • Moderate follicular and paracortical hyperplasia
Findings of a veterinary pathologist (IK), upon analysis of H&E, Masson's Trichrome and anti-collagen-I
stained slides of peripheral lymph nodes.
doi:10.1371/journal.ppat.1005146.t002
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degree of collagen deposition in the T-cell zones of this animal were at similar levels to those
seen in HIV-1 infected animals at only week two p.i. Increased collagen deposition was also
observed in the PALS of the spleen of the two deceased SIVcpz infected animals.
Analysis of immune activation in the peripheral lymphoid tissues
Progressive HIV and SIV infections are associated with chronic immune activation measurable
in the secondary lymphoid tissues. Mx1 (also known as MxA) is an antiviral factor with no
activity against HIV-1 [22], but which is upregulated in response to type I interferon stimula-
tion. Persistent expression of Mx1 in the lymph node distinguishes pathogenic and non-patho-
genic lentiviral infections [23], as it is rapidly down-regulated after acute infection in African
‘natural host’ species. In the three experimentally infected animals, Mx1 staining was elevated
at week two post-infection compared to uninfected controls in the T-cell zone (Fig 6). These
levels were reduced by week 12/16, remaining elevated at this time point only in Ch-Ni. In the
chronic phase of infection, levels of Mx1 in the T-cell zone was significantly elevated compared
to uninfected controls. In particular, the naturally infected animal Ch-No had high levels of
Mx1, approaching the levels found in SIVmac infected rhesus macaques, included here to pro-
vide additional context. At the transcriptional level, Mx1 expression in PBMCs was only ele-
vated more than two fold in the week two sample. The expression patterns of other known
Type I interferon modulated genes is shown in S5 Fig.
Proliferating T-cells in the lymph node were also measured, by quantifying the number of
Ki-67 positive cells in the T-cell zone of the lymph node (S6 Fig). There were no significant dif-
ferences in chronic HIV-1 or SIVcpz infection compared to uninfected animals, though there
were highly elevated levels in the animal Ch-Ni in the acute phase of infection.
Autoimmune anti-platelet antibodies in SIVcpz infected animals
Chronic thrombocytopenia has previously been reported for Ch-No [16]. In addition, of the
five experimentally infected animals with post infection platelet counts available, two had
platelet counts falling within the bottom 5th percentile for their age and gender category (5th
percentile for adult males = 130.5 x109/l, for adult females = 150.87 x109/l [24]). Chronic
thrombocytopenia is also reported for Cam-155, a naturally SIVcpz infected chimpanzee
housed in a primate sanctuary in Cameroon with AIDS like clinical signs [25]. Noting that
auto-immune antibodies against platelet glycoproteins GP II/IIIa and GP Ib/Ix are associated
with thrombocytopenia in SIV infected rhesus macaques [26], the presence of such antibodies
Fig 4. Lymphoid hyperplasia in SIVcpz infected chimpanzees. Representative images from one uninfected chimpanzee, and the three available lymph
node samples from chronic SIVcpz infected chimpanzees (detailed in Table 2). Arrow indicates the one normal follicle visible in the image from the uninfected
animal.
doi:10.1371/journal.ppat.1005146.g004
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was determined in this cohort. A plasma sample from Cam-155 was also available for analysis
and included here (this sample was excluded from other analyses as it was exposed to poor
storage conditions, but was included here due to the relative stability of antibody molecules,
and after confirmation of IgG presence by a Protein A capture ELISA). Thus, the presence of
these antibodies were tested in a total of 8 animals (7 described in Table 1, and Cam-155).
Most strikingly, antibodies against GP II/IIIa were found in 5 of 8 SIVcpz infected animals,
including all four animals determined to have thrombocytopenia or low platelet counts, Fig 7.
Fig 5. Collagen deposition in SIVcpz infected animals. (A) Representative images of anti- CD3 and anti-
collagen 1 immunostainings of lymph nodes from an uninfected chimpanzee and from the chronically SIVcpz
infected chimpanzee Ch-Ni. (B) Quantification of collagen I in T-cell zones from experimentally infected
animals in early and chronic infection. (C) Comparison of the same parameter in uninfected chimpanzees
(n = 6) and chronic HIV-1 (n = 5), and chronic SIVcpz (n = 3) infected chimpanzees. Horizontal black bars
indicate the mean value in each group. Group details provided in S7 Table. * indicates P<0.05 in a Kruskal–
Wallis Test with Dunn’s post test. (D) Representative images of splenic PALS of two uninfected animals and
the two SIVcpz infected animals for which spleen samples were available.
doi:10.1371/journal.ppat.1005146.g005
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Measurement of soluble CD14
No significant difference between chronic SIVcpz infected animals and HIV-1 or uninfected
animals was found in the concentration of plasma soluble CD14 (Fig 8a). Levels of sCD14 were
also compared between uninfected chimpanzees housed in primate research centres in the U.S
Fig 6. Analysis of Mx1 expression in the lymph nodes of SIVcpz infected chimpanzees. (A) Representative images of anti-Mx1 staining in the T-cell
zones of a lymph node of an uninfected chimpanzee, and of Ch-Ni at week 2 and 12 post infection, and at necropsy. (B) Proportion of lymph node T-cell
zones staining for anti-Mx1 staining over the course of experimental SIVcpz infection. (C) The same analysis in uninfected chimpanzees (n = 6), chronic HIV-
1 infected (n = 5) chronic SIVcpz infected chimpanzees (n = 3), uninfected rhesus macaques (RM neg, n = 3) and SIVmac infected rhesus macaques (RM
SIV, n = 3). Horizontal black bars indicate the mean value in each group. * indicates P<0.05 in a Kruskal–Wallis test with Dunn’s post test. (D) Transcription
level expression of Mx1 in PBMCs in the RNA-seq cohort, numbers indicate fold upregulation compared to the control group (n = 3).
doi:10.1371/journal.ppat.1005146.g006
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and Europe, with the levels found in chimpanzees housed at the International Centre of Medi-
cal Research, Franceville (CIRMF), Gabon. Notably, levels of sCD14 were significantly greater
in animals housed in the African primate centre than in animals housed in the US or Europe
(Fig 8b).
Discussion
The finding that wild chimpanzees of the schweinfurthii subspecies in the Gombe national
park were at greater risk of mortality when infected with SIVcpz [7] has led to the view that
SIVcpz infection of chimpanzees presents a greater risk of a pathogenic outcome than SIV
Fig 7. Prevalence of anti-platelet autoimmune antibodies. The presence of anti-platelet antibodies,
specific for the glycoprotein (GP) complexes IIb/IIIa, Ia/IIa and Ib/IX was determined in plasma from
uninfected, HIV-1 infected and SIVcpz infected animals. The prevalence of these antibodies in the four
animals with low platelet counts is also shown.
doi:10.1371/journal.ppat.1005146.g007
Fig 8. Levels of plasma soluble CD14 in uninfected and SIVcpz infected chimpanzees. (A) Levels of
plasma sCD14 were determined in uninfected and chronic HIV-1 and SIVcpz infected chimpanzees. (B)
Levels of sCD14 in uninfected chimpanzees held in two primate centres in the US and Europe, compared
with chimpanzees housed at the CIRMF, Gabon. Horizontal black bars indicate the mean value in each
group. ** indicates a P-value of <0.01 in a Mann-Whitney U test, two tailed.
doi:10.1371/journal.ppat.1005146.g008
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infection of other African primates. This is of particular significance as SIVcpz is the source of
HIV-1 in humans, and is one of only a few SIVs to share specific viral features with HIV-1,
such as the presence of the vpu gene, and the failure of Nef to down-regulate CD3 [11].
We present here the first long-term study of multiple SIVcpz infected chimpanzees, housed
in primate centres in the US and Europe, conditions similar to the majority of studies of sooty
mangabeys and African green monkeys, upon which our understanding of SIV infection of Afri-
can ‘natural host’ primate species is based. Most notably, SIVcpz infection in this cohort was not
associated with the development of an AIDS like disease. In all of the animals that have died post
infection, death was attributed to cardiac disease. While HIV-1 infection of humans is associated
with heart disease [27], it should be noted that deaths related to cardiac problems are common
in captive chimpanzees, particularly in males [28]. This has been studied in chimpanzees at
Texas Biomedical Research Institute (formally Southwest Foundation), where the majority of
animals in this cohort were housed. The mean age of death in male chimpanzees dying of heart
disease is approximately 26, with deaths from heart disease noted as young as 10 years old at this
centre [28]. As such, it is not necessary to assume an effect of SIVcpz infection on the develop-
ment of heart disease in three animals reported here, which died 18, 22 and 33 years of age.
Despite a lack of AIDS-defining illnesses or deaths in this cohort, SIVcpz infection was asso-
ciated with significant depletion of CD4+ T-cells. This is consistent with the findings of CD4
+ T-cell loss in naturally infected animals in the wild [7], and the two investigated chimpanzees
in captivity in primate facilities in Africa [25,29]. However, despite the loss of CD4+ T-cells in
SIVcpz infected animals in this study, SIVcpz infection shared features with the non-patho-
genic infection of sooty mangabeys and African green monkeys with their species-specific
viruses. In particular, SIV infection of natural host species is associated with a rapid reduction
in innate and adaptive immune activation after the acute phase, while in pathogenic infection
of humans and Asian primates, immune activation persists throughout the chronic phase. In
the peripheral blood of the chimpanzees studied here, soluble and cellular markers of immune
activation reverted to normal levels shortly after acute infection, as occurs in other well studied
natural hosts [9,30]. The mechanisms by which immune activation is brought under control in
even the most well studied species remains controversial.
The low viral load at several of the chronic time-points observed here could explain the low
levels of immune activation found in this study. However, it should be noted that in most mea-
surements, immune activation was brought rapidly under control after only weeks of infection,
despite relatively high viral loads for at least the first year of infection in all animals. Secondly,
peripheral blood immune activation was also low in the naturally infected animal, Ch-No,
despite relatively high viral loads (4–5 log copies/ml) throughout.
Progressive HIV and SIV infections are also associated with pathological changes to the
structure of the secondary lymphoid environment. Interestingly, unlike markers of activation
in the peripheral blood, persistent and significant changes were evident in the peripheral lym-
phoid tissues of SIVcpz infected animals. These included follicular hyperplasia, increased levels
of Mx1 expression, and increased deposition of collagen, all of which are features of pathogenic
lentiviral infection. Indeed, it is these features that most strongly differentiate the chimpanzees
studied here from other SIV infected natural hosts. Some persistent changes, including CD4
loss, increased T-cell activation and an increased levels of transcription of interferon induced
genes can be identified through flow cytometric and transcriptional analysis of SIV infected
African green monkeys and sooty mangabeys [9,10,30,31]. However, changes in the lymphoid
tissues to not appear to be shared with other African primate species. Follicular hyperplasia has
never been found to be associated with SIV infection of other natural hosts [32–34], and both
collagen deposition and chronic increased Mx1 expression (as measured at the protein level),
segregate pathogenic and non-pathogenic infection models [23,35,36].
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Thus, combined with the findings of Keele et al [7], it would appear that significant changes to
the secondary lymphoid tissue structure, including collagen deposition, are features that segregate
SIVcpz infection of chimpanzees from the SIV infections of any other African primate, regardless
of study setting. It should be noted for future studies that these phenomena occurred here without
changes of comparable magnitude in assays of the blood, in terms of the systemic immune activa-
tion that accompanies such changes in the lymphoid tissues in other species where this occurs. It
is possible that a greater sensitivity to detect changes in immune activation would have been
achieved if specific subsets (specifically non-naïve subsets) of CD4+ and CD8+ T-cells were
examined, but unfortunately such measurements could not be carried out with samples available.,
It is also worth noting however that most papers that describe significant T-cell activation in HIV
infected humans have generally studied entire CD4 and CD8 populations [17–21,37]
The possibility that SIVcpzANT is a naturally attenuated virus must be considered. That all
the animals in this cohort were infected with the same strain of SIVcpz is a major limitation in
using this study to draw broader conclusions about the outcome of SIVcpz infection. Unfortu-
nately, it is extremely difficult to determine if SIVcpzANT differs significantly from other
SIVcpz isolates. While host factors play a large role in the outcome of HIV-1 infection of
humans, naturally occurring attenuated HIV-1 viruses have been isolated and sequenced from
long term non-progressor HIV-1 infected patients (reviewed in [38]). Mutations in these
viruses which might explain how they are susceptible to host immune response, replication
impaired, or in any other way attenuated, only become apparent by comparison with the vast
number of HIV-1 sequences available from patients showing a typical course of disease. By
contrast, sequences of SIVcpz from schweinfurthii subspecies animals are limited to SIVcp-
zANT, closely related sequences from the Gombe cohort in Tanzania (SIVcpzTAN), and only
two additional sequences (a full-length genome from an animal in the DRC SIVcpzBF1167,
and a partial genome from an animal in Uganda, SIVcpzUG31. Without additional, more
closely related sequences for comparison, in addition to known outcomes of infection, there is
no readily apparent methodology to determine if SIVcpzANT has features that would class it
as a naturally attenuated virus. The most that can be said is that SIVcpzANT is lacking any
large-scale gene deletions or nonsense mutations, such as nef deletions found in some long-
term non-progressor human patients [39,40]. Furthermore, it has been shown that SIVcp-
zANT nef cannot downregulate CD3, as with other SIVcpz isolates [11].
While there is no evidence of an AIDS like disease in these captive SIVcpz infected animals,
the results here are not entirely contradictory with the findings in wild chimpanzees. Firstly, it
bears restating that the known causes of death of the wild SIVcpz infected animals, trauma and
massive parasite infection, are unlikely to occur in captive animals. However, as in wild chim-
panzees, SIVcpz infection of these captive animals was associated with a loss of CD4+ T-cells.
Furthermore, SIVcpz infection was associated with changes to the secondary lymphoid struc-
ture and increased collagen deposition in the spleen, as in wild chimpanzees.
Given that CD4+ T-cell loss is thought to be linked to immune activation in pathogenic
infections, the relatively low levels of chronic immune activation seen in these captive animals
most likely explains why CD4+ T-cell loss is only a gradual process. Furthermore, it could be
suggested that additional sources of immune activation in the wild environment may lead to
more rapid loss of CD4+ T-cells in wild chimpanzees.
In addition to the finding that wild SIVcpz infected chimpanzees suffer from increased mor-
tality, one case of an AIDS like disease has been reported [25], and three more orphan SIVcpz
infected chimpanzees have been reported to die rapidly following rescue to African primate
centres or sanctuaries [41–43]. While the rapid deaths of some of these orphan chimpanzees
was not proposed to be AIDS related at the time of the reports, the causes of death are notable
in light of Keele et al; subacute pneumonia, parasite infection and severe diarrhea. It could be
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proposed that such African primate sanctuararies/centres are in many respects intermediate
between the environment that the chimpanzees in this study were housed in, and the wild.
While captive chimpanzees in African primate centres or sanctuaries have veterinary supervi-
sion, they have greater exposure to the natural environment, including the use of local fauna in
both the food and enrichment materials. Exposure to infectious agents may be greater than in
the environments of US/European primate research centres and sanctuaries—and if not
greater, certainly different. The suggestion that these environments may be different in ways
relevant to the outcome of SIVcpz infection is supported by the finding that soluble sCD14 lev-
els are significantly different in animals housed in the US/European primate centres compared
to animals housed at the CIRMF, Gabon. sCD14 is produced by a number of cell types in
response to the bacterial cell wall molecule lipopolysaccharide (LPS), and thus elevated levels
of sCD14 may indicate greater exposure to LPS. sCD14 has been used as a surrogate marker for
integrity of the gut mucosal barrier, which is lost during progression to AIDS in pathogenic
infections, and levels of soluble CD14 in HIV-1 infected humans predicts rate of disease pro-
gression [44,45]. Notably, pig-tailed macaques infected with SIV/SHIV are a model for AIDS,
with generally rapid disease progression, and susceptibility to AIDS from a number of viruses
that are not able to cause disease in rhesus macaques. It has been demonstrated that pre-infec-
tion, the gut mucosal barrier of these animals is frequently compromised, and these animals
have higher levels of immune activation pre-infection than rhesus macaques [46]. Crucially,
the level of bacterial translocation (as measured by levels of plasma LPS-binding protein) pre-
infection is predictive of the rate of disease progression post infection [47]. Thus it seems possi-
ble that the higher levels of sCD14 in chimpanzees held in an African primate centre may be
partly responsible for the apparent increased susceptibility to disease progression following
SIV infection in wild and captive chimpanzees in Africa.
An additional finding that may explain the increased mortality found in wild African chim-
panzees, but not these captive animals infected with SIVcpz, is the trend observed here for
SIVcpz infection to be associated with anti-platelet antibodies and thrombocytopenia. Thro-
mobocytopenia is a common complication of HIV-1 infected humans, occurring in 10–30% of
HIV-1 infected patients [48,49]. The development of anti-GPIIIa antibodies (shown here to
have the most compelling relationship between SIVcpz infection and thrombocytopenia in the
chimpanzee cohort) has been shown to be specifically associated with patients developing
HIV-1 associated immune thrombocytopenia [50]. It has previously been reported that molec-
ular mimicry between HIV-1 gp120 and human gpIIIa leads to the development of this anti-
body in humans [51]. Identification of similar mimicry between SIVcpz gp120 and
chimpanzee platelet proteins was beyond the scope of this study. Interestingly, chimpanzees
infected with HIV-1 have also been documented as developing thrombocytopenia, in the pres-
ence of high levels of anti gpIIIa antibodies [52].
While under high levels of veterinary care, such as is found in primate centres and sanctuar-
ies, the outcome of chronic thrombocytopenia is less likely to be severe than in the wild.
Indeed, while Ch-No frequently suffers from nose-bleeds, the chronic thrombocytopenia from
which this animal has suffered for over 15 years has yet to cause any life-threatening complica-
tions. In contrast, the chimpanzees in the Gombe national park live under more physically and
environmentally demanding conditions. Clearly, a chronic thrombocytopenia is more likely to
be life-threatening where aggressive encounters, high parasitic burdens, stress and trauma are
more likely. Indeed, it can be questioned how long Ch-No, which has suffered from a profound
thrombocytopenia from age 9 years, would have survived in the wild.
The question as to if the wild environment affects the outcome of SIV infection in other
African primate species has recently been addressed by ourselves and others. Ma et al’s studies
of wild African green monkeys [53,54], of exceptional scope and scale, found very few
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perturbations of the immune system in SIVagm infected monkeys. By contrast, our own study
of naturally SIVmnd-1 infected mandrills, held in a ‘semi-wild’ environment, revealed signifi-
cant loss of memory CD4+ T-cells, and significantly increased immune activation in infected
animals [34]. These features of SIVmnd-1 infection were not found in captive, experimentally
infected mandrills [55], suggesting that the wild environment may indeed alter the outcome of
SIV infection.
While this study is limited by the relatively small number of SIVcpz infected chimpanzees
and incomplete sample availability, it should be noted that future experiments involving
SIVcpz infection of chimpanzees are extremely unlikely, due to changes in ethical and legal
limitations placed on invasive research on chimpanzees in the period since these experiments
were instigated. Thus, this work, based on retrospective analysis of stored samples and follow
up of animals involved in earlier experiments provides the most thorough investigation to date,
and for the foreseeable future, of the effect of SIVcpz infection on the immune system of cap-
tive chimpanzees.
To conclude, the history of SIVcpz infection of captive chimpanzees shares a number of fea-
tures of both pathogenic and non-pathogenic infection. In common with the non-pathogenic
SIV infection of well-studied African primates, the SIVcpz infected chimpanzees studied here
rapidly control immune activation (when measured in the peripheral blood), and they appear
to maintain the gut mucosal barrier. However, SIVcpz infection is associated with loss of CD4
+ T-cells, and significant immune activation in the lymph node, and with changes in the struc-
ture of the secondary lymphoid environment. In the captive environment, these effects are
insufficient to cause an overt AIDS-like disease, but do distinguish SIVcpz infection of chim-
panzees from the SIV infections of other African primates. Thus, the virus-host relationship in
SIVcpz infected chimpanzees appears to be intermediate between that found in well described
‘natural hosts’ and in species in which SIV/HIV infection leads to disease. Damage to the
immune system in this cohort of captive SIVcpz infected chimpanzees was insufficient to lead
to AIDS-like disease, but nevertheless, significant disruptions to the immune system were
found, perhaps explaining why SIVcpz infected animals in the wild suffer an adverse outcome.
Materials and Methods
Animals
Experimental infection protocols have been described previously [16]. Animals Ch-No and
Ch-Ni were housed at the BPRC, Netherlands, until the death of Ch-Ni in 2005, and the trans-
fer of Ch-No to the Rescue Centre for Exotic Animals ‘Stichting AAP’. Animals X062, X310,
X284, X176 and X115 were housed at the Texas Biomedical Research Institute. X115 was sub-
sequently transferred to ‘Chimp Haven’ in 2006. Cam155 has been described previously, and
was housed at the Ape Action Africa (AAA) sanctuary, Yaoundé, Cameroon at the time of
sampling. Data from uninfected and HIV-1 infected animals were obtained from sexually
mature chimpanzees (over age 7 years). HIV-1 infected chimpanzees were all infected for
greater than five years at the date of data used.
Ethics statement
Experimental infection of animals has been reported previously and was approved by the TBRI
(formerly Southwest Foundation for Biomedical Research, SFBR, Animal Welfare Assurance
Number A3082-01) IACUC, with the protocol assigned number 130-PT-4. Additional blood
draws from animals held at Texas Biomedical were approved under protocol numbers 181-PT-
3 and 825-PT-0. Experimental infection of Ch-Ni was approved by the IACUC of the BPRC,
protocol 914a (DEC-004). Blood draws from uninfected and HIV-1 infected animals at the
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BPRC were approved under protocols 84-6A and 101–7 (DEC-029). Data was also acquired
from HIV-1 and SIVcpz infected animals held at Chimp Haven, Louisiana, during an annual
health check. When animals were anaesthetised and blood was already to be drawn for veteri-
nary control purposes, a small volume of additional blood was taken to carry out flow cyto-
metric and viral load analysis. Results were returned to veterinary staff of Chimp Haven to aid
in the care of these animals. An additional blood draw for this purpose was approved by the
ethical review board of Chimp Haven and assigned protocol number 2010–02. The use of
residual blood drawn from Cam155, AAA, Cameroon, and uninfected chimpanzees at the
CIRMF Gabon, taken for veterinary purposes during routine health checks, and remaining
after these assays were carried out, was approved by the Ethical committee of the Department
of Veterinary Medicine, University of Cambridge, with the approved protocol logged as CR90.
At Stichting AAP, Ch-No was sedated annually in order to monitor his health, with focus on
his thrombocytopenia and viral status. A small amount of blood was collected extra for cyto-
metric and viral load analysis. This was performed under supervision of AAP’s Board of
Experts and was agreed in a covenant between the Dutch government, the BPRC and Stichting
AAP in June 2003.
Housing of animals in all centres complied with the Guide for the Care and Use of Labora-
tory Animals (TBRI) or The European Council Directive 86/609/EEC (BPRC, CIRMF, AAP,
AAA). Animals in all centres were housed in spacious cages or open air ‘corrals’. Animals at
the BPRC and TBRI and AAP were provided with commercial food pellets supplemented with
appropriate treats, while animals at the CIRMF were fed with various Gabonese fruits and veg-
etables, a “home-made” protein complement cake, and other snacks between meals. In all
cases, drinking water was provided ad libitum. In all cases, environmental enrichment was in
all centres through swings, hammocks, raised platforms within the enclosures, and through the
addition of supplementary toys, which were changed regularly. The housing conditions at the
BPRC and AAP have also been described extensively previously [56]. All blood draws were
taken under anaesthesia, ketamine/HCl, 10 mg/(kg body weight), and all efforts were made to
minimise animal suffering. No chimpanzees were sacrificed for this study, and all post-mortem
materials were recovered after death from other causes.
Determination of lentiviral load
QC-PCR analysis of viral loads was carried out as previously described [57]. A pol based
qRT-PCR assay was designed to replace this assay based on pol clones derived from the
plasma of Ch-No, generated by nested PCR, along with previously published SIVcpz
sequences. A lack of polymorphism in the selected region was confirmed by analysis of
sequences generated by Illumina sequencing of RNA sequences from plasma at week two p.i.
from Ch-Ni. The primers selected were GGTAATGGCAGATGAGACAGG (forward) and
TGGATTCCACTACTCCTTGAC (reverse), with the probe JOE-GGCCATCTGCTGGC
TAATTTTAACAGGAA-BHQ1, where JOE is the fluorochrome and BHQ1 is the quencher
(Black Hole Quencher 1). Comparison of samples measured with both the QC-PCR and
qRT-PCR assays showed reasonable agreement (S3 Fig).
To carry out the assay, RNA was extracted from 200 μl of plasma using the Roche High
Pure Viral RNA kit as per manufacturer protocol. Extracted RNA (in a total of 50 μl) was sup-
plemented with RNAsin Plus RNase inhibitor (Promega) at one unit per μl and immediately
frozen at -80°C. Frozen RNA was thawed on ice, and 10 μl of RNA was added to 10ul real-time
reaction mastermix (Taqman Fast Virus One-step real-time PCR Mastermix, including prim-
ers and probe). Serial dilution of a plasmid bearing the pol region of SIVcpzANT was used as a
standard. The real-time assay was carried out on a Rotorgene 6000 (Qiagen) using the
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following protocol; 5 min at 50°C (for reverse transcription), 20 s at 90°C (to inactivate the
reverse transcriptase and for initial denaturation), followed by 40 cycles of 95°C for 3 s and
60°C for 30 s. This assay did not detect HIV-1, as confirmed by using plasmids containing the
pol of HIV-1 IIIB and SF2.
HIV-1 viral loads were determined using the QC-PCR assay [57], or a taqman assay as
described previously [58]. Viral loads of HIV-1 infected chimpanzees were generally low. Of
the 29 HIV-1 non-progressor animals included in Fig 1, on the date of data shown, 18 had viral
loads<100 copies/ml, two had viral loads between 100 and 1000 copies/ml, and three had viral
loads between 1000 and 5000 copies/ml. Six animals did not have their HIV-1 viral loads deter-
mined on the same date, but other measurements for these animals fell in the same range
(<100 to 5x104 copies/ml). As previously described, in SIVcpz infected animals that were
infected with HIV-1 at the point of SIVcpz infection, HIV-1 viral loads were detectable only in
X310 and X115 at the point of infection. HIV-1 viral loads of X310 were consistently between
<200–500 copies/ml until the point of death. HIV-1 viral loads of X115 were also between
2x102 and 5x103 during the first year of SIVcpz infection, but have been<100 copies/ml in
every sample taken subsequently.
Analysis of plasma markers and auto-immune antibodies
Plasma samples were stored at -80°C until use. Commercial ELISAs were used to determine
the concentration of soluble markers of immune activation or auto-immune antibodies. The
suppliers of these assay are listed in parentheses; sCD14 (Abcam), sTRAIL (Abcam), β2 micro-
globulin (IBL international), Neopterin (IBL neopterin), PAKAUTO assay for anti-platelet
antibodies (Gen-Probe). All assays were used according to manufacturer protocol, using frozen
plasma, with the exception that packed platelet samples were unavailable for the PAKAUTO
assay, and therefore only free antibodies in plasma could be measured. All samples were
assayed together at the University of Cambridge after shipment on dry ice from the respective
centres involved.
Flow cytometry
Flow cytometry on fresh samples was carried out on whole blood. 100 μl of whole blood was
incubated with the antibody mixture for 15 min at room temperature in the dark, in round bot-
tomed polystyrene tubes (BD Biosciences). The sample was treated with FACS lysing solution
(BD Biosciences) for 10 min in the dark to lyse erythrocytes, centrifuged, and washed with 2 ml
of PBS with 1% bovine serum albumin. Finally, the cells were fixed with 2% paraformaldehyde
in PBS overnight and analyzed. Due to the long period of time of this study and the different
centres involved, analysis was carried out on number of different flow cytometers (FACSscan,
FACScalibur, LSR-II or FACSAria, all manufactured by BD Biosciences).
Staining of cryopreserved samples was carried out to acquire data on Ki-67 expression in
retrospective samples as indicated. At the time of sampling, PBMCs were isolated over a Ficoll-
Pacque gradient (GE healthcare) and frozen in a medium of 90% foetal calf serum, 10%
Dimethyl sulfoxide. An initial gradual temperature decline was achieved using a ‘Mr Frosty’
(Nalgene) container with isopropanol and a -80°C freezer. Once frozen, samples were stored in
a liquid nitrogen container. Samples were thawed quickly at 37°C, washed once in warm
RPMI-1640 including benzonaze (50 units/ml), and incubated for 1 hour at 1x106 cells/ml in
RPMI-1640 with 10% FCS for one hour at 37°C, to allow restoration of cell membrane integ-
rity. 1 ml (1x106) cells were then transferred to round bottomed polypropylene tubes (BD Bio-
sciences), centrifuged, and resuspended in 100 μl of antibody mixture in PBS, including a
viability marker to allow the exclusion of dead cells after acquisition.
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Antibodies against the following markers were used, with the clone name in parentheses, all
supplied by BD; CD3ε (SP34.2), CD4 (SK3), CD8 (SK1), CD16 (3G8), CD20 (L27), CD69
(FN50), MHC-II (anti-HLA-DR, L243), Ki-67 (B56).
Transcriptomics analysis
PBMC pellets containing 5x106 PBMCs were snap frozen at the indicated time-point. Pellets
were resuspended in 0.5 ml Qiazol (Qiagen) and incubated for 5 m at room temperature. RNA
extraction was then performed using the Qiagen RNeasy Lipid Tissue mini kit, as per manufac-
turer instructions, including on-column DNA digest. RNAsin Plus (Promega) RNA inhibitor
was added to eluted RNA, and RNA samples were stored at -80°C at this point. As RNA yield
was low, the Ovation RNA-Seq FFPE kit (Nugen) was used, as per manufactures instructions
to provide sufficient cDNA for the standard Illumina RNA-seq protocol, with 100bp paired
reads, carried out by the TGAC sequencing centre, Norwich. As the RNA yield was limiting,
some samples were excluded at this point, and for almost all samples, all purified RNA was
required for the amplification and subsequent sequencing processes. qRT-PCR validation of
this data-set could therefore not be carried out. Analysis of sequencing data was carried out
using the CLC genomics platform. Sequence data received from the TGAC (8–70 million reads
per sample) was trimmed to remove low complexity and low quality reads. Subsequently, reads
were mapped to the chimpanzee annotated genome (Ensemble CHIMP 2.1.4.74), resulting in
approximately 70% of reads mapping uniquely to the chimpanzee genome, with each read in a
pair counting once, to allow inclusion of reads mapping as a broken pair, and pairs broken dur-
ing the trimming process. Total numbers of unique gene reads were normalised to the number
of mapped reads per sample, and this number was used for intergroup comparisons. Heatmaps
were generated using the gplot package, executed in R [59]. Genes were selected for inclusion
for figures on the basis that reads were detected in all available samples and had a more than
two-fold difference in any group compared to the control group. Heatmaps shown in the main
body figures include genes relevant to the post-translational measurements within the same fig-
ures. S4 Fig shows genes that were more than twofold up or down regulated in any group com-
pared to the uninfected control, that were more than two-fold upregulated in a human in vitro
T-cell activation study at 24, 48 or 72 hours post activation [60]. S5 Fig shows genes that were
more than twofold up or down regulated in any group compared to the uninfected controls,
that appear more in more than 10 datasets when queried on the human interferome, version
2.01 [61].
Open access to the transcriptomics reads is available from the ENA under accession
ERP009138. S7 Table gives the number of reads per gene in each sample, per million reads.
Immunohistochemistry
Immunohistological examination was performed on sections of formalin fixed, paraffin
embedded tissues. Unfortunately, as animal X310 died during the night, and was not discov-
ered until the morning, tissues from this animal were subject to autolysis sufficient to render
them unusable for analysis. Following dewaxing, heat-induced epitope-retrieval was carried
out using the PT link module (Dako), before they were stained using the EnVision FLEX Kit
(Dako) in combination with a Dako Autostainer according to the manufacturer protocol. Pri-
mary antibodies against the following molecules were used, with the clone name, manufacturer
and dilution factor in parentheses; CD3 (F7.2.38, Dako, 1:300), Ki-67 (M1B-1, Dako, 1:150),
MX1 (polyclonal #95926, Abcam, 1:500), Collagen-1 (Rabbit polyclonal, ab34710, Abcam,
1:500). Collagen-I staining of samples from rhesus macaques were excluded from the analysis,
as similar intensity of staining could not be achieved compared to chimpanzees.
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Quantitative tissue analysis
Slides were scanned using a Nanozoomer 2.0 brightfield whole-slide scanner (Hamamatsu) at
40x magnification. For analysis of lymphoid hyperplasia, the outline of follicles was traced
manually on scans of H&E stained slides, using ImageScope (Version 17, Aperio), which out-
puts the area of the object outlined. Quantitative analysis of Mx1 and Collagen-I was also car-
ried out on ImageScope. T-cell zones were traced on CD3+ slides (stained on consecutively cut
slides) and superimposed onto Mx1 or Collagen-1 slide scans. The proportion of the area stain-
ing for these markers was then determined using the positive pixel count tool within
ImageScope.
To quantify the number of Ki-67+ cells within the T-cell zone a slightly different approach
was used. 0.01 mm2 areas were captured from individual T-cell zones in the Ki-67 stained slide
(based on the CD3+ stained slide) at 40x magnification. A selection of these images from sev-
eral different animals was then used to train an image classifier in Ilastik (version 0.5 [62]). Ilas-
tik is a machine learning programme. Areas representing Ki-67+ and Ki-67- cells, in addition
to the background are manually specified by tracing onto the images selected. Ilastik then uses
this information to generate a classifier that can be used to define these three groups in any
image. Cellprofiler (version 2.0 [63]) was then used to count the number of Ki-67+ cells. A cell-
profiler pipeline was constructed to import all Ki-67+ images in turn, and use the classifier
defined by Ilastik to define Ki-67+ areas. The object counting module was then used to define
individual Ki-67+ cells based on size and shape parameters determined empirically. This
allowed for objective counting of cells even where positive cells were closely clustered.
Statistical analysis
General linear models were used to determine the effect of HIV-1 and SIVcpz infection, in
addition to age and gender, after variables were transformed where necessary to produce nor-
mally distributed data. This analysis was carried out using the R platform [59]. Where data
could not be normalised satisfactorily, or where the number of values was too low to allow con-
fidence that data was appropriately distributed, a Kruskall-Wallis test with Dunn’s multiple
comparison was carried out using Prism 5.0 (Graphpad).
Supporting Information
S1 Fig. Longitudinal measurements of viral load and CD4+ T-cell count in Ch-No. Viral
load was measured using a quantitative competitive PCR (QC-PCR) or a reverse transcriptase,
real-time PCR (qRT-PCR) (see S3 Fig). Broken black line indicates limit of detection of the
viral load assays (250 copies/ml).
(PDF)
S2 Fig. Longitudinal CD4+ T-cell counts and viral loads in the experimentally SIVcpz
infected chimpanzees. Absolute peripheral blood CD4+ T-cell counts are indicated in blue,
while viral loads (determined with the qRT-PCR assay are displayed in red). Time points in the
first year of infection for which viral load data were available are indicated on the axis in red
numerals, as differences in availability of samples results in apparent differences in early
dynamics of the viral load. Broken blue and red lines indicate long periods between data points.
The broken black line indicates the limit of detection of the viral load assay (250 copies/ml).
(PDF)
S3 Fig. Comparison of the QC-PCR and qRT-PCR viral load assays. Viral load was mea-
sured using a quantitative competitive PCR (QC-PCR) or a reverse transcriptase, real-time
PCR (qRT-PCR) as described in the methods section. (A) Viral loads determined on the same
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samples with both assays showed a good correlation in samples from Ch-No, where the use of
both methods was required due to lack of availability of samples to repeat measurements with
the qRT-PCR assay.
(PDF)
S4 Fig. T-cell activation associated gene expression in PBMCs. Transcription level expres-
sion of genes known to be upregulated in human in vitro activated T-cells that were or down
regulated by at least two fold in any group compared to the control animals in the RNAseq
cohort (n = 3).
(PDF)
S5 Fig. Interferon inducible gene expression in PBMCs. Transcription level expression of
known interferon inducible genes in PBMCs in the RNA-seq cohort that were up or down reg-
ulated by at least two fold in any group compared to the control animals (n = 3).
(PDF)
S6 Fig. Analysis of Ki-67 expression in the T-cell zones of SIVcpz infected chimpanzees.
(A) Representative images of anti-Ki-67 staining in the T-cell zones of a lymph node of an
uninfected chimpanzee, and of Ch-Ni at week 2 and 12 post infection, and at necropsy. (B)
Number of Ki-67+ cells in the T-cell zone of lymph nodes over the course of experimental
infection and (C) in chronic SIVcpz infected chimpanzees, SIVmac infected rhesus macaques
and control animals. Horizontal black bars indicate the mean value in each group.
(PDF)
S1 Table. Summary of the age and gender attributes for SIVcpz and control chimpanzee
groups for CD4+ T-cell analysis (Fig 1).
(XLS)
S2 Table. Details and coefficients of statistical analysis used in (Fig 1).
(XLS)
S3 Table. Summary of the age and gender attributes for SIVcpz and control chimpanzee
groups for T-cell activation analysis (Fig 2b).
(XLS)
S4 Table. Details and coefficients of statistical analysis used in T-cell activation analysis
(Fig 2b).
(XLS)
S5 Table. Summary of the age and gender attributes for SIVcpz and control chimpanzee
groups for transcriptomics analysis.
(XLS)
S6 Table. Summary of the age and gender attributes for SIVcpz and control chimpanzee
groups for soluble marker analysis (Fig 3).
(XLS)
S7 Table. Details of samples used for histological and immunohistochemical analyses.
(XLS)
S8 Table. Transcriptomics data analysis values. Values are total reads mapping to each gene,
normalised to the number of reads mapped in each sample. All time-points post-infection (or
pre-infection, indicated by a negative value) are related to SIVcpz (not HIV-1) infection.
(XLS)
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